Drug Profile


Alternative Names: BHT 920; Domin

Latest Information Update: 31 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Class Antiparkinsonians; Azepines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Parkinson's disease
  • Discontinued Psychotic disorders

Most Recent Events

  • 31 May 2006 No development reported - Phase-II for Parkinson's disease in USA (PO)
  • 31 May 2006 No development reported - Phase-III for Parkinson's disease in Germany (PO)
  • 31 May 2006 No development reported - Preclinical for Parkinson's disease in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top